R-(-)-3-Quinuclidinol API CAS# 25333-42-0 Producers

Looking for R-(-)-3-Quinuclidinol API 25333-42-0?

Description:

Here you will find a list of producers, manufacturers and distributors of R-(-)-3-Quinuclidinol. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.

API | Excipient name:

R-(-)-3-Quinuclidinol 

Cas Number:

25333-42-0 

R-(-)-3-Quinuclidinol is a type of Neurokinin antagonists

Neurokinin antagonists are a subcategory of pharmaceutical active pharmaceutical ingredients (APIs) that target the neurokinin receptors in the body. These receptors are part of the neurokinin system, which plays a vital role in regulating various physiological processes, including inflammation, pain transmission, and vomiting.

Neurokinin antagonists work by blocking the binding of neurokinins, such as substance P, to their receptors. Substance P is a neuropeptide that transmits pain signals and triggers inflammation in the body. By inhibiting the binding of substance P, neurokinin antagonists can help reduce pain and inflammation.

Furthermore, neurokinin antagonists have shown potential in managing various conditions, including chemotherapy-induced nausea and vomiting, irritable bowel syndrome, and psychiatric disorders such as depression and anxiety. Their mechanism of action in these conditions involves modulating the neurokinin system, which can help alleviate symptoms and improve patient outcomes.

Due to their therapeutic potential, neurokinin antagonists have gained considerable attention in the pharmaceutical industry. Researchers and pharmaceutical companies are actively exploring novel neurokinin antagonists with improved efficacy and reduced side effects.

In conclusion, neurokinin antagonists are a valuable subcategory of pharmaceutical APIs that target the neurokinin system. Their ability to inhibit the binding of substance P and modulate neurokinin receptors makes them promising candidates for the treatment of various conditions associated with pain, inflammation, and vomiting. Ongoing research and development efforts aim to enhance the therapeutic potential of these compounds and expand their applications in the field of medicine.

R-(-)-3-Quinuclidinol (Neurokinin antagonists), classified under Central Nervous System Agents

Central Nervous System (CNS) Agents are a crucial category of pharmaceutical Active Pharmaceutical Ingredients (APIs) that specifically target the central nervous system. The CNS encompasses the brain and spinal cord, playing a vital role in regulating and controlling various bodily functions, including cognition, movement, emotions, and sensory perception. These agents are designed to interact with specific receptors, enzymes, or ion channels within the CNS to modulate neural activity and restore normal functioning.

CNS agents comprise a diverse range of pharmaceutical APIs, including analgesics, anesthetics, antipsychotics, sedatives, hypnotics, anti-epileptics, and antidepressants. Each subcategory addresses distinct neurological disorders and conditions. For instance, analgesics alleviate pain by targeting receptors in the brain and spinal cord, while antipsychotics are employed to manage psychosis symptoms in mental illnesses such as schizophrenia.

The development of CNS agents involves rigorous research, molecular modeling, and extensive clinical trials to ensure safety, efficacy, and specific target engagement. Pharmaceutical companies invest significant resources in identifying novel drug targets, synthesizing new compounds, and optimizing their pharmacological properties. These agents undergo rigorous regulatory evaluations and must adhere to stringent quality standards and guidelines.

Given the prevalence of CNS disorders globally, the market demand for effective CNS agents is substantial. The development of innovative CNS APIs not only improves patient outcomes but also provides valuable commercial opportunities for pharmaceutical companies. Continued advancements in CNS agent research and development hold the promise of groundbreaking therapies that can improve the quality of life for individuals affected by neurological conditions.